Phytoestrogens and risk of prostate cancer: an updated meta-analysis of epidemiologic studies.
This updated meta-analysis was performed to clarify the relationship between phytoestrogens and prostate cancer risk. Twenty one case-control and two cohort studies were finally selected for this meta-analysis, totaling 11,346 cases and 140,177 controls. Analytical results showed that daidzein (OR = 0.85; 95% CI: 0.75-0.96), genistein (OR = 0.87; 95% CI: 0.78-0.98), and glycitein (OR = 0.89; 95% CI: 0.81-0.98) were associated with a reduction of prostate cancer risk, but total isoflavones (OR = 0.93; 95% CI: 0.84-1.04), equol (OR = 0.86; 95% CI: 0.66-1.14), total lignans (OROgna.05; 95% CI: 0.54-2.04), secoisolariciresinol (OR = 1.02; 95% CI: 0.83-1.24), matairesinol (OR = 0.91; 95% CI: 0.75-1.11), enterolactone (OR = 0.94; 95% CI: 0.73-1.20), and coumestrol (OR = 0.89; 95% CI: 0.76-1.06) were not. Sensitivity and publication bias analyses demonstrated that the pooled estimates were stable and reliable. The results support the notion that some phytoestrogens may have a role in decreasing the risk of prostate cancer. Additional large and well-designed cohort studies are needed to confirm these relationships.
a School of Public Health, Jiamusi University , Jiamusi , China.
Qiang
Q
Zhang
a School of Public Health, Jiamusi University , Jiamusi , China.|b Department of Neurology , Zhongnan Hospital of Wuhan University , Wuhan , China.
Hongliang
H
Feng
a School of Public Health, Jiamusi University , Jiamusi , China.
Bakare
B
Qluwakemi
a School of Public Health, Jiamusi University , Jiamusi , China.
Jiaqi
J
Wang
a School of Public Health, Jiamusi University , Jiamusi , China.
Songpo
S
Yao
c College of Life Science, Jiamusi University , Jiamusi , China.
Guangdong
G
Cheng
d College of Basic Medicine, Jiamusi University , Jiamusi , China.
Hui
H
Xu
a School of Public Health, Jiamusi University , Jiamusi , China.
Hongbin
H
Qiu
a School of Public Health, Jiamusi University , Jiamusi , China.
Liling
L
Zhu
e Bio-Vaccine Limited Liability Company, Harbin Pharmaceutical Group , Harbin , China.
Mingxia
M
Yuan
D016022:Case-Control Studies; D015331:Cohort Studies; D000072001:Diet, Healthy; D019317:Evidence-Based Medicine; D019833:Genistein / Q000627:therapeutic use; D006801:Humans; D007529:Isoflavones / Q000627:therapeutic use; D008297:Male; D054526:Men's Health; D048789:Phytoestrogens / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D012306:Risk
D007529:Isoflavones; D048789:Phytoestrogens; C004742:daidzein; C086566:glycitein; D019833:Genistein
Phytoestrogens; isoflavones; meta-analysis; prostate cancer; risk